Sofosbuvir, also known as PSI-7977 and GS7977 (brand names Sovaldi and Virunon), is a drug used for hepatitis C virus (HCV) infection, with a high cure rate. It inhibits the RNA polymerase that the hepatitis C virus uses to replicate its RNA. It was discovered at Pharmasset and developed by Gilead Sciences. Sofosbuvir is a component of the first all-oral, interferon-free regimen approved for treating chronic Hepatitis C. In 2013, the FDA approved sofosbuvir in combination with ribavirin (RBV) for oral dual therapy of HCV genotypes 2 and 3, and for triple therapy with injected pegylated interferon (pegIFN) and RBV for treatment-naive patients with HCV genotypes 1 and 4.
MedKoo Cat#: 314202
Name: Sofosbuvir
CAS#: 1190307-88-0
Chemical Formula: C22H29FN3O9P
Exact Mass: 529.1625
Molecular Weight: 529.45
Elemental Analysis: C, 49.91; H, 5.52; F, 3.59; N, 7.94; O, 27.20; P, 5.85
| Solvent | mg/mL | mM | comments | |
|---|---|---|---|---|
| Solubility | ||||
| DMSO | 73.3 | 138.50 | ||
| Ethanol | 62.5 | 118.05 | ||
| Water | 25.0 | 47.22 | ||
| PBS (pH 7.2) | 0.2 | 0.38 | ||
| DMF | 20.0 | 37.78 |
The following data is based on the product molecular weight 529.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
